SG10201607345YA - Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions - Google Patents
Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditionsInfo
- Publication number
- SG10201607345YA SG10201607345YA SG10201607345YA SG10201607345YA SG10201607345YA SG 10201607345Y A SG10201607345Y A SG 10201607345YA SG 10201607345Y A SG10201607345Y A SG 10201607345YA SG 10201607345Y A SG10201607345Y A SG 10201607345YA SG 10201607345Y A SG10201607345Y A SG 10201607345YA
- Authority
- SG
- Singapore
- Prior art keywords
- lxr
- modulators
- disorders
- liver
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606160P | 2012-03-02 | 2012-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201607345YA true SG10201607345YA (en) | 2016-11-29 |
Family
ID=49083313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607345YA SG10201607345YA (en) | 2012-03-02 | 2013-02-28 | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| SG11201405378VA SG11201405378VA (en) | 2012-03-02 | 2013-02-28 | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405378VA SG11201405378VA (en) | 2012-03-02 | 2013-02-28 | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8987318B2 (OSRAM) |
| EP (2) | EP3441390A1 (OSRAM) |
| JP (2) | JP6378630B2 (OSRAM) |
| KR (1) | KR102112879B1 (OSRAM) |
| CN (1) | CN104284893B (OSRAM) |
| AU (1) | AU2013225840B2 (OSRAM) |
| BR (1) | BR112014021515A2 (OSRAM) |
| CA (1) | CA2866113C (OSRAM) |
| CY (1) | CY1120742T1 (OSRAM) |
| DK (1) | DK2820013T3 (OSRAM) |
| ES (1) | ES2691079T3 (OSRAM) |
| HR (1) | HRP20181623T1 (OSRAM) |
| HU (1) | HUE040231T2 (OSRAM) |
| IL (1) | IL234413B (OSRAM) |
| LT (1) | LT2820013T (OSRAM) |
| MX (1) | MX361349B (OSRAM) |
| NZ (1) | NZ629636A (OSRAM) |
| PL (1) | PL2820013T3 (OSRAM) |
| PT (1) | PT2820013T (OSRAM) |
| RS (1) | RS57863B9 (OSRAM) |
| SG (2) | SG10201607345YA (OSRAM) |
| SI (1) | SI2820013T1 (OSRAM) |
| SM (1) | SMT201800630T1 (OSRAM) |
| TR (1) | TR201815013T4 (OSRAM) |
| WO (1) | WO2013130892A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2820013T (pt) | 2012-03-02 | 2018-10-25 | Ralexar Therapeutics Inc | Moduladores do recetor x do fígado (lxr) para o tratamento de doenças dérmicas, distúrbiose condições |
| CN105188380B (zh) * | 2013-03-15 | 2017-08-15 | 百时美施贵宝公司 | Lxr调节剂 |
| CN104151300B (zh) * | 2013-05-15 | 2018-07-13 | 中国医学科学院医药生物技术研究所 | 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途 |
| DK3041835T3 (da) | 2013-09-04 | 2020-07-13 | Ellora Therapeutics Inc | Modulatorer af lever-X-receptorer (LXR) |
| SG11201601644RA (en) | 2013-09-04 | 2016-04-28 | Alexar Therapeutics Inc | Liver x receptor (lxr) modulators |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| US20190365784A1 (en) | 2015-12-30 | 2019-12-05 | Raúl Enrique MASSONE | Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators |
| CN109069461A (zh) | 2016-01-11 | 2018-12-21 | 洛克菲勒大学 | 与髓源性抑制细胞相关的病症的治疗方法 |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| WO2021009664A1 (en) | 2019-07-15 | 2021-01-21 | Novartis Ag | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| WO2022249006A1 (en) * | 2021-05-24 | 2022-12-01 | Novartis Ag | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1199771A (en) * | 1915-07-01 | 1916-10-03 | Bates Valve Bag Co | Wire-twisting machine. |
| WO2002024632A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| CA2486651A1 (en) | 2002-05-24 | 2003-12-04 | Pharmacia Corporation | Sulfone liver x-receptor modulators |
| CA2486644A1 (en) | 2002-05-24 | 2003-12-04 | Pharmacia Corporation | Anilino liver x-receptor modulators |
| ES2361924T3 (es) | 2002-12-20 | 2011-06-24 | X-Ceptor Therapeutics, Inc. | Derivados de isoquinolinona y su uso como agentes terapéuticos. |
| JP2006193426A (ja) | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−４（３ｈ）−オン化合物 |
| WO2005113499A1 (ja) | 2004-05-20 | 2005-12-01 | Sankyo Company, Limited | インドール化合物 |
| WO2006003923A1 (ja) | 2004-06-30 | 2006-01-12 | Sankyo Company, Limited | 置換ベンゼン化合物 |
| PA8640701A1 (es) | 2004-08-03 | 2006-09-08 | Wyeth Corp | Indazoles utiles para tratamiento de enfermedades cardiovascular |
| US20070060589A1 (en) * | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| WO2006109633A1 (ja) | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | 置換インドール化合物 |
| US7213797B2 (en) | 2005-05-20 | 2007-05-08 | Garland Jerome Gaskins | Deck board straightener |
| EP1910307A1 (en) | 2005-06-27 | 2008-04-16 | Exelixis, Inc. | Pyrazole based lxr modulators |
| SG162803A1 (en) * | 2005-06-27 | 2010-07-29 | Exelixis Inc | Imidazole based lxr modulators |
| HRP20100542T1 (hr) | 2005-09-16 | 2010-11-30 | Arrow Therapeutics Limited | Derivati bifenila i njihova uporaba za liječenje hepatitisa c |
| WO2007034279A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| US20090062260A1 (en) | 2005-11-14 | 2009-03-05 | Irm Llc | Compounds and compositions as lxr modulators |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| TW200825054A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| AU2007333194A1 (en) | 2006-12-08 | 2008-06-19 | Exelixis, Inc. | LXR and FXR modulators |
| US8338437B2 (en) * | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| WO2009020683A2 (en) | 2007-05-18 | 2009-02-12 | Wyeth | Quinazoline compounds |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| MX2010001742A (es) | 2007-08-13 | 2010-03-10 | Hoffmann La Roche | Nuevos derivados de piperazina-amida. |
| CN101952257A (zh) | 2007-12-21 | 2011-01-19 | 惠氏有限责任公司 | 苯并咪唑化合物 |
| US20110112135A1 (en) | 2007-12-21 | 2011-05-12 | Singhaus Jr Robert Ray | Imidazo [1,2-A] Pyridine Compounds |
| CA2724232A1 (en) * | 2008-05-13 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
| US8063088B2 (en) | 2008-06-11 | 2011-11-22 | Hoffmann-La Roche Inc. | Imidazolidine derivatives |
| CA2741537A1 (en) | 2008-11-07 | 2010-05-14 | Wyeth Llc | Quinoxaline-based lxr modulators |
| CA2742023A1 (en) | 2008-11-19 | 2010-05-27 | Wyeth Llc | Polar quinazolines as liver x receptors ( lxrs ) modulators |
| TW201034666A (en) | 2008-12-22 | 2010-10-01 | Schering Corp | Gamma secretase modulators |
| WO2010096170A2 (en) * | 2009-02-19 | 2010-08-26 | President And Fellows Of Harvard College | Inhibition of trna synthetases and therapeutic applications thereof |
| CA2753313A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| SI2435410T1 (sl) | 2009-05-28 | 2017-06-30 | Bristol-Myers Squibb Company | Lxr modulatorji |
| ES2620177T3 (es) | 2009-10-15 | 2017-06-27 | Guerbet | Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas |
| GB0919757D0 (en) | 2009-11-12 | 2009-12-30 | Johnson Matthey Plc | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| JPWO2012020820A1 (ja) * | 2010-08-11 | 2013-10-28 | 大正製薬株式会社 | ヘテロアリール−ピラゾール誘導体 |
| CN106905311A (zh) * | 2010-08-27 | 2017-06-30 | 钙医学公司 | 调节细胞内钙的化合物 |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| PT2820013T (pt) | 2012-03-02 | 2018-10-25 | Ralexar Therapeutics Inc | Moduladores do recetor x do fígado (lxr) para o tratamento de doenças dérmicas, distúrbiose condições |
| CA3211094A1 (en) | 2012-08-13 | 2014-02-20 | The Rockefeller University | Treatment and diagnosis of melanoma |
| SG11201601644RA (en) | 2013-09-04 | 2016-04-28 | Alexar Therapeutics Inc | Liver x receptor (lxr) modulators |
| DK3041835T3 (da) | 2013-09-04 | 2020-07-13 | Ellora Therapeutics Inc | Modulatorer af lever-X-receptorer (LXR) |
-
2013
- 2013-02-28 PT PT13754329T patent/PT2820013T/pt unknown
- 2013-02-28 MX MX2014010537A patent/MX361349B/es active IP Right Grant
- 2013-02-28 SG SG10201607345YA patent/SG10201607345YA/en unknown
- 2013-02-28 PL PL13754329T patent/PL2820013T3/pl unknown
- 2013-02-28 KR KR1020147027825A patent/KR102112879B1/ko not_active Expired - Fee Related
- 2013-02-28 DK DK13754329.4T patent/DK2820013T3/en active
- 2013-02-28 RS RS20181179 patent/RS57863B9/sr unknown
- 2013-02-28 AU AU2013225840A patent/AU2013225840B2/en not_active Ceased
- 2013-02-28 EP EP18182346.9A patent/EP3441390A1/en not_active Withdrawn
- 2013-02-28 HR HRP20181623TT patent/HRP20181623T1/hr unknown
- 2013-02-28 CA CA2866113A patent/CA2866113C/en not_active Expired - Fee Related
- 2013-02-28 ES ES13754329.4T patent/ES2691079T3/es active Active
- 2013-02-28 BR BR112014021515-4A patent/BR112014021515A2/pt active Search and Examination
- 2013-02-28 SG SG11201405378VA patent/SG11201405378VA/en unknown
- 2013-02-28 SM SM20180630T patent/SMT201800630T1/it unknown
- 2013-02-28 WO PCT/US2013/028438 patent/WO2013130892A1/en not_active Ceased
- 2013-02-28 EP EP13754329.4A patent/EP2820013B9/en active Active
- 2013-02-28 CN CN201380018482.7A patent/CN104284893B/zh not_active Expired - Fee Related
- 2013-02-28 LT LTEP13754329.4T patent/LT2820013T/lt unknown
- 2013-02-28 TR TR2018/15013T patent/TR201815013T4/tr unknown
- 2013-02-28 SI SI201331198T patent/SI2820013T1/sl unknown
- 2013-02-28 JP JP2014560060A patent/JP6378630B2/ja not_active Expired - Fee Related
- 2013-02-28 NZ NZ629636A patent/NZ629636A/en not_active IP Right Cessation
- 2013-02-28 HU HUE13754329A patent/HUE040231T2/hu unknown
-
2014
- 2014-09-01 IL IL234413A patent/IL234413B/en active IP Right Grant
- 2014-09-02 US US14/474,490 patent/US8987318B2/en not_active Expired - Fee Related
-
2015
- 2015-02-12 US US14/621,255 patent/US9637481B2/en not_active Expired - Fee Related
-
2017
- 2017-04-03 US US15/477,140 patent/US20170334897A1/en not_active Abandoned
-
2018
- 2018-04-18 US US15/956,389 patent/US20180370959A1/en not_active Abandoned
- 2018-08-02 JP JP2018145589A patent/JP6800922B2/ja not_active Expired - Fee Related
- 2018-10-08 CY CY181101037T patent/CY1120742T1/el unknown
-
2020
- 2020-05-13 US US15/931,403 patent/US20210101895A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL234413B (en) | Liver x receptor modulators for the treatment of diseases and skin disorders | |
| IL269852B (en) | Combined treatments and uses for the treatment of demyelination disorders | |
| ZA201500561B (en) | Compositions and treatment for eye diseases and disorders | |
| HUE041553T2 (hu) | Lizoszomális tárolási betegségek (LSD) kezelése és génterápia | |
| IL225239A0 (en) | Compounds for the treatment of acne and related diseases | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| AP2014007804A0 (en) | Compositions and methods for the treatment of hepatic diseases and disorders. | |
| IL232334A0 (en) | Modulators of the G protein-coupled mas receptor and the treatment of related disorders | |
| IL225668A (en) | Formulations for the treatment of disorders of the upper respiratory tract | |
| IL235058A0 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| ZA201504065B (en) | Therapeutic agent for keratoconjunctive disorders | |
| PL392436A1 (pl) | Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| EP2934501A4 (en) | USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES | |
| IL237912B (en) | History of dihydro-6-azaphenylene for the treatment of the central nervous system, oncological diseases and similar disorders | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| PL395469A1 (pl) | Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego | |
| HK40066378A (zh) | 用於治疗肝脏疾病和障碍的组合物和方法 | |
| HK40043513B (en) | Interval therapy for the treatment of eye diseases | |
| IL245511A0 (en) | Compositions and methods for treating viral diseases with 4pde modulators | |
| AU2012900788A0 (en) | Combination treatment for rheumatic disorders | |
| AU2012904982A0 (en) | Device for treating respiratory disorders |